Evaluation of a Cytomegalovirus Prophylaxis Protocol in Cytomegalovirus-IgG Positive Renal Transplant Recipients (R+).

[1]  V. Vinuesa,et al.  Regular monitoring of cytomegalovirus-specific cell-mediated immunity in intermediate-risk kidney transplant recipients: predictive value of the immediate post-transplant assessment. , 2019, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[2]  R. Selgas,et al.  La infección por citomegalovirus postrasplante renal y pérdida del injerto a largo plazo , 2017 .

[3]  V. Miller,et al.  Definitions of Cytomegalovirus Infection and Disease in Transplant Patients for Use in Clinical Trials. , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  R. Selgas,et al.  Cytomegalovirus infection after kidney transplantation and long-term graft loss. , 2017, Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia.

[5]  A. Webster,et al.  Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients. , 2013, The Cochrane database of systematic reviews.

[6]  A. Uysal,et al.  Cytomegalovirus and rubella seroprevalence in pregnant women in Izmir/Turkey: follow-up and results of pregnancy outcome , 2012, Archives of Gynecology and Obstetrics.

[7]  V. Kliem,et al.  Additional evidence to support routine cytomegalovirus prophylaxis for all D+/R+ renal graft recipients. , 2012, Transplantation.

[8]  D. Çolak,et al.  [Investigation of cytomegalovirus seroepidemiology in Antalya with a population-based cross-sectional study and review of related data in Turkey]. , 2007, Mikrobiyoloji bulteni.

[9]  A. Limaye,et al.  Impact of Cytomegalovirus in Organ Transplant Recipients in the Era of Antiviral Prophylaxis , 2006, Transplantation.

[10]  A. Webster,et al.  Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials , 2005, The Lancet.

[11]  T. Reischig,et al.  A randomized prospective controlled trial of oral ganciclovir versus oral valacyclovir for prophylaxis of cytomegalovirus disease after renal transplantation , 2002, Transplant international : official journal of the European Society for Organ Transplantation.

[12]  D. Schoenfeld,et al.  Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis , 2000, Transplant infectious disease : an official journal of the Transplantation Society.

[13]  H. Balfour,et al.  A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. , 1989, The New England journal of medicine.